The European Society for Medical Oncology (ESMO) has published updated recommendations on the management of patients with relapsed epithelial ovarian carcinoma.
ESMO now recommends maintenance therapy with a poly-ADP-ribose-polymerase (PARP) inhibitor (olaparib, niraparib or rucaparib) following a response to platinum-based therapy in patients with recurrent platinum-sensitive high-grade ovarian cancer as a new standard of care option, irrespective of BRCA status.
For patients with recurrent platinum-sensitive ovarian cancer and a BRCA mutation who are unable to receive platinum-based therapy, rucaparib monotherapy is an option.
Announcing the eUpdate, ESMO commented: “Following the results of the first randomised maintenance trial with olaparib demonstrating a significant improvement in progression-free survival (PFS), particularly in patients with a BRCA mutation, further data has emerged and three other phase 3 trials with other PARP inhibitors have been conducted. The evidence shows that maintenance therapy with niraparib, rucaparib or olaparib (tablet formulation) after platinum-based chemotherapy for recurrent ovarian cancer has a wider clinical benefit.”
A PFS benefit is seen with all three drugs, not only in tumours with a BRCA mutation or a somatic mutation but also in BRCA wild-type tumours.